Skip to main content
EJNMMI Research
Fig. 4 | EJNMMI Research

Fig. 4

From: The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor

Fig. 4

A single dose of AZD8186 (50 mg/kg) shows a pharmacodynamic knock down of PI3K pathway activity in both PTEN null cell line models and not in PI3Kαin correlation with imaging data. a 786-0 model. b U87-MG model. c BT474C model. Data is represented as mean ±SEM. pAKT expression represented by MSD, Western blot and IHC analysis; pPRAS40 expression represented with ELISA, Western blot and IHC analysis. IHC n = 5/group. MSD and Western blots n > 8/group. Representative images for Western blot (±AZD8186) and IHC analysis (×20 magnification) are also shown

Back to article page